Arovella Therapeutics Ratios and Metrics

Market cap in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb '26 Feb 18, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Market Capitalization	107	118	147	42	15	27
Market Cap Growth	-45.29%	-19.46%	246.10%	175.83%	-43.79%	420.70%
Enterprise Value	86	107	142	39	11	22
Last Close Price	0.09	0.10	0.14	0.05	0.02	0.06
PS Ratio	31.18	34.44	75.34	29.21	52.08	27.69
PB Ratio	5.34	5.90	13.10	11.24	2.02	3.05
P/TBV Ratio	5.34	5.90	13.10	11.24	2.06	3.10
EV/Sales Ratio	25.11	31.02	72.90	26.83	37.85	22.28
Debt / Equity Ratio	-	-	-	-	0.02	0.01
Net Debt / Equity Ratio	-1.04	-1.04	-1.13	-1.37	-0.78	-0.74
Net Debt / EBITDA Ratio	2.68	2.68	1.44	0.61	0.79	1.74
Net Debt / FCF Ratio	2.84	2.84	1.81	0.81	0.94	1.79
Asset Turnover	0.20	0.20	0.21	0.20	0.03	0.11
Quick Ratio	14.06	14.06	6.32	3.08	4.05	4.28
Current Ratio	14.18	14.18	6.45	3.22	4.37	4.33
Return on Equity (ROE)	-47.98%	-47.98%	-116.55%	-178.67%	-103.87%	-76.96%
Return on Assets (ROA)	-28.30%	-28.30%	-59.16%	-73.48%	-47.72%	-28.43%
Return on Capital Employed (ROCE)	-39.30%	-39.30%	-78.90%	-227.80%	-98.60%	-44.00%
Earnings Yield	-7.00%	-6.34%	-5.95%	-23.96%	-55.95%	-18.42%
FCF Yield	-6.85%	-6.20%	-4.79%	-15.06%	-40.91%	-13.54%
Buyback Yield / Dilution	-16.55%	-16.55%	-32.32%	-29.45%	-66.10%	-132.61%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.